Biomarker Strategies: Trends & Patient Impact

This event ran on Tuesday May 25, 2021 | 11:00am EST | 8:00am PST

Engager Hosted by
Guardant Health


The May Guardant Health Engager will cover:

Biomarker Strategies: Trends & Patient Impact


Welcome to the Guardant Health Engager, an exclusive limited-attendance event that focuses on the impact of disruptive, data-driven biopharma-based strategies to accelerate drug development and improve cancer patient care. We are inviting you to this event among other high-level executives from biopharma based in the US and Europe.

This event will delve into the short and long-term strategic decisions that drive your diagnostic investments in the next 3-5 years. For instance, our KOL panel will discuss biomarker-informed patient treatments across the continuum of patient care, and in support of such disruptive treatments, the underlying technological advances and innovative partnership models across drug and diagnostic developers, medical centers and payors.

We hope you will find this a thought-provoking discussion on strategies to accelerate clinical trials, extract value from cutting-edge biomarker innovation, and expand therapeutic access for cancer patients. We thank you for your consideration and look forward to sharing our vision of conquering cancer with data.


  • Learn how to treat cancer across the continuum of care: Trends per indication and key trials showcasing earlier access to patients
  • Review technological trends (e.g., multiomics): Causative vs. correlative biomarkers
  • An outlook on accelerating clinical trials and data/Real World Evidence (RWE)-driven strategies
  • Discuss different commercialization strategies, such as ex-US and market access
  • Explore emerging drivers of change: How are evolving partnership models between biopharma manufacturers, diagnostic companies, academic medical centers and patient advocacy groups affecting patient treatments?


Following a Q&A, attendees can connect with key Guardant Health executives and members to converse and dig a bit deeper into the topics covered throughout the session.

This is an exclusive limited-attendance event for Heads, VPs, C-Level leaders of biopharma precision medicine groups looking to get an overview of how data-driven biomarker-based strategies can help accelerate drug development and ultimately, improve cancer patient care.




Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets, and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched liquid biopsy-based Guardant360®, Guardant360 CDx, and GuardantOMNI® tests for advanced stage cancer patients, and Guardant Reveal™ test for early-stage cancer patients. These tests fuel development of its LUNAR screening program, which aims to address the needs of asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection.